---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000797"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T07:32:14.464143+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Teva Q1 revenue $3.7B flat YoY; non-GAAP EPS $0.40 down from $0.55; reaffirms FY 2023 outlook

## Summary
- Revenues $3,661M flat YoY (up 4% local currency); GAAP loss per share ($0.18) improved from ($0.86).
- Non-GAAP diluted EPS $0.40 vs $0.55 YoY; adjusted EBITDA $899M, down 21% from $1,135M.
- Non-GAAP gross margin 49.1%, down from 54.2% due to inflationary pressures and unfavorable mix.
- AUSTEDO grew 10% YoY and AJOVY grew 35% (local currency); UZEDY approved for schizophrenia.
- Full-year 2023 outlook reaffirmed: revenue $14.8-15.4B, non-GAAP EPS $2.25-2.55, free cash flow $1.7-2.1B.

## SEC filing metadata
- accession: 0001157523-23-000797
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000115752323000797/0001157523-23-000797-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000115752323000797/a53397230.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000797
- JSON: https://secwatch.observer/filing/0001157523-23-000797.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000797.txt

## Key facts
- Earnings Releases
  TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended March 31, 2023 results: revenue $3,661 million, EPS GAAP loss per share of $0.18; Non-GAAP diluted EPS of $0.40. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2023
  - Revenue: $3,661 million
  - EPS: GAAP loss per share of $0.18; Non-GAAP diluted EPS of $0.40
  - Guidance: reaffirmed
  - Result: reported results
  source text: where we will make decisive choices and focus our resources to drive growth and innovation." First Quarter 2023 Consolidated Results Revenues in the first quarter of 2023 were $3,661 million, flat compared to the first quarter of 2022. In local currency terms, revenues increased by 4%, mainly due to higher revenues from generic products in our Europe and
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000115752323000797/0001157523-23-000797-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.